Brian Elenbaas

7.4k total citations · 2 hit papers
26 papers, 4.1k citations indexed

About

Brian Elenbaas is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Brian Elenbaas has authored 26 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 18 papers in Oncology and 4 papers in Genetics. Recurrent topics in Brian Elenbaas's work include Cancer-related Molecular Pathways (9 papers), RNA modifications and cancer (8 papers) and Virus-based gene therapy research (4 papers). Brian Elenbaas is often cited by papers focused on Cancer-related Molecular Pathways (9 papers), RNA modifications and cancer (8 papers) and Virus-based gene therapy research (4 papers). Brian Elenbaas collaborates with scholars based in United States, Germany and Japan. Brian Elenbaas's co-authors include Robert A. Weinberg, Arnold J. Levine, William C. Hahn, Jiayuh Lin, Mark D. Fleming, Suman Lee, Jack Griffith, Mary W. Brooks, Jean‐Claude Nicolas and Vincent Maréchal and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Brian Elenbaas

26 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells

2001 677 citations Brian Elenbaas, Lisa Spirio et al. Genes & Development profile →
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.

1994 561 citations Brian Elenbaas, Arnold J. Levine et al. Genes & Development profile →

Peers

Countries citing papers authored by Brian Elenbaas

Since Specialization

Citations

This map shows the geographic impact of Brian Elenbaas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Elenbaas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Elenbaas more than expected).

Fields of papers citing papers by Brian Elenbaas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Elenbaas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Elenbaas. The network helps show where Brian Elenbaas may publish in the future.

Co-authorship network of co-authors of Brian Elenbaas

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Elenbaas. A scholar is included among the top collaborators of Brian Elenbaas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Elenbaas. Brian Elenbaas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab 2023 ·Scientific Reports ·Shota Fukuoka, Yoshikatsu Koga, (unknown), (unknown), Masahiro Yasunaga, Kohei Shitara, Toshihiko Doi, Takayuki Yoshino, (unknown), Brian Elenbaas, (unknown), Hong Zhang, (unknown), Molly H. Jenkins, (unknown), Takashi Kojima	6
2	Abstract 2153: ATR inhibition augments the efficacy of the lurbinectedin in small cell lung cancer 2022 ·Cancer Research ·Christopher W. Schultz, Yang Zhang, (unknown), Yasuhisa Murai, Darawalee Wangsa, (unknown), Liton Kumar Saha, Brian Elenbaas, (unknown), (unknown), Thomas Ried, Frank T. Zenke, Zoë Weaver Ohler, Rajaâ El Meskini, Yves Pommier, Anish Thomas	2
3	Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy 2019 ·Frank T. Zenke, Astrid Zimmermann, Heike Dahmen, Brian Elenbaas, John D. Pollard, Philip M. Reaper, (unknown), (unknown), (unknown), Andree Blaukat	1
4	Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy 2019 ·Cancer Research ·Frank T. Zenke, Astrid Zimmermann, Heike Dahmen, Brian Elenbaas, John R. Pollard, Philip M. Reaper, Shubha Bagrodia, Mary E. Spilker, Christiane Amendt, Andree Blaukat	15
5	MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models 2018 ·Oncotarget ·Francesca Vena, (unknown), (unknown), Juan José García-Gómez, Manuel Rodriguez‐Justo, Jianguo Ma, (unknown), (unknown), Brian Elenbaas, (unknown), John A. Hartley, Daniel Hochhauser	32
6	Abstract 139: M2698, a novel dual inhibitor of p70S6K and Akt: preclinical efficacy in gastric cancer 2017 ·Cancer Research ·Shota Fukuoka, Takashi Kojima, Yoshikatsu Koga, (unknown), Masahiro Yasunaga, Yasuhiro Matsumura, Toshihiko Doi, Takayuki Yoshino, (unknown), (unknown), Brian Elenbaas, A. Ohtsu	1
7	Structure-based design of low-nanomolar PIM kinase inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·Alexey Ishchenko, Lin Zhang, (unknown), Junhua Fan, (unknown), (unknown), (unknown), Latika Singh, Brian Elenbaas, Victor Sukbong Hong, (unknown), Laura Silvian, Istvan Enyedy, Jianhua Chao	17
8	105 BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors 2010 ·European Journal of Cancer Supplements ·Brian Elenbaas, Lata Singh, Antonio Boccia, Peter J. Cullen, (unknown), Eva Rohde, (unknown), (unknown), Ingrid B.J. Joseph	4
9	Identification of SFRP1 as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer 2005 ·Cancer Research ·(unknown), Steve Perrin, Brian Elenbaas, Stephen E. Fawell, Jeffrey S. Rubin, Omar E. Franco, Simon W. Hayward, Gerald R. Cunha, Paul C. Marker	129
10	Immortalization and transformation of primary human airway epithelial cells by gene transfer 2002 ·Oncogene ·Ante S. Lundberg, Scott H. Randell, Sheila A. Stewart, Brian Elenbaas, Kimberly A. Hartwell, Mary W. Brooks, Mark D. Fleming, John C. Olsen, Scott W. Miller, Robert A. Weinberg, William C. Hahn	190
11	Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation 2002 ·Molecular and Cellular Biology ·William C. Hahn, Scott Dessain, Mary W. Brooks, Jessie E. King, Brian Elenbaas, David M. Sabatini, James A. DeCaprio, Robert A. Weinberg	494
12	Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells breakdown → 2001 ·Genes & Development ·Brian Elenbaas, Lisa Spirio, F. Koerner, Mark D. Fleming, Drazen B. Zimonjic, Joana Liu Donaher, Nicholas C. Popescu, William C. Hahn, Robert A. Weinberg	677
13	Heterotypic Signaling between Epithelial Tumor Cells and Fibroblasts in Carcinoma Formation 2001 ·Experimental Cell Research ·Brian Elenbaas, Robert A. Weinberg	433
14	Rules governing the creation of human tumor cells 2001 ·European Journal of Cancer ·(unknown), Brian Elenbaas, Sheila A. Stewart, Randolph S. Watnick, Jian Yang, Sendurai A. Mani, R A Weinberg	2
15	Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis 1997 ·Oncogene ·Vincent Maréchal, Brian Elenbaas, Lisa A. Taneyhill, (unknown), Marcel Méchali, Jean‐Claude Nicolas, Arnold J. Levine, Jacques Moreau	34
16	Alternatively Spliced Forms in the Carboxy-Terminal Domain of the p53 Protein Regulate Its Ability to Promote Annealing of Complementary Single Strands of Nucleic Acids 1995 ·Molecular and Cellular Biology ·Lin Wu, J. Henri Bayle, Brian Elenbaas, Nikola P. Pavletich, Arnold J. Levine	99
17	p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches 1995 ·Cell ·Suman Lee, Brian Elenbaas, Arnold J. Levine, Jack Griffith	347
18	The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. 1995 ·Proceedings of the National Academy of Sciences ·J. Henri Bayle, Brian Elenbaas, Arnold J. Levine	89
19	The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. 1994 ·Molecular and Cellular Biology ·Vincent Maréchal, Brian Elenbaas, Jacques Piette, Jean‐Claude Nicolas, A J Levine	266
20	Two upstream elements activate transcription of a major histocompatibility complex class I genein vitro 1992 ·Nucleic Acids Research ·Paul H. Driggers, Brian Elenbaas, Jiabin An, (unknown), Keiko Ozato	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact